Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
GRAIL is a pre-commercial stage precision oncology company developing multi-cancer early detection (MCED) blood tests, with its lead product Galleri designed to detect 50+ cancer types through circulating tumor DNA analysis. The company operates in the emerging liquid biopsy market with significant first-mover advantages in MCED technology, though it remains deeply unprofitable with $600M+ annual cash burn as it navigates FDA approval pathways and builds commercial infrastructure. Stock performance is driven by clinical validation milestones, regulatory progress, reimbursement decisions, and partnership announcements rather than traditional financial metrics.
GRAIL's business model centers on commercializing its proprietary cell-free DNA methylation sequencing platform that analyzes blood samples to detect cancer signals before symptoms appear. The company charges approximately $949 per Galleri test in the self-pay market, with economics improving dramatically if Medicare coverage is secured (estimated 40+ million eligible beneficiaries aged 50-80). Competitive advantages include extensive clinical validation data from 140,000+ participant studies (PATHFINDER, SUMMIT), proprietary methylation-based detection algorithms with 99.5% specificity, and substantial IP portfolio covering MCED methodologies. The path to profitability requires achieving regulatory clearance (FDA Breakthrough Device designation obtained), securing favorable CMS reimbursement decisions, and scaling test volumes to 1M+ annually to leverage fixed R&D costs across larger revenue base.
FDA regulatory milestones - De Novo classification decision timeline, advisory committee meetings, approval/rejection announcements for Galleri test
CMS reimbursement decisions - Medicare coverage determinations (LCD/NCD), reimbursement rate announcements, PAMA pricing updates
Clinical trial data releases - PATHFINDER 2, REFLECTION study results, real-world evidence on cancer detection rates and stage shifts
Commercial adoption metrics - test volume growth rates, healthcare system partnerships (NHS England contract), employer/health plan coverage decisions
Competitive developments - Exact Sciences, Freenome, Guardant Health MCED program updates, comparative performance data
Regulatory approval uncertainty - FDA may require additional clinical evidence, impose restrictive labeling, or deny De Novo classification, delaying or preventing commercialization of Galleri test
Reimbursement risk - CMS may decline Medicare coverage, set inadequate reimbursement rates below cost, or impose restrictive coverage criteria that limit addressable market to small patient subsets
Clinical validation challenges - Real-world performance may not replicate trial results, false positive rates could trigger unnecessary downstream procedures and payer pushback, or competing technologies may demonstrate superior performance
Capital intensity - Pathway to profitability requires $2B+ cumulative investment with no guarantee of commercial success, creating ongoing dilution risk and potential need for strategic alternatives if funding markets close
Exact Sciences developing multi-cancer blood test leveraging existing Cologuard commercial infrastructure and payer relationships, with potential cost advantages from integrated screening portfolio
Guardant Health's Shield CRC test establishing liquid biopsy reimbursement precedent, with MCED programs in development backed by strong balance sheet and oncology franchise
Academic medical centers and diagnostic labs developing proprietary MCED assays that could fragment market and pressure pricing
Single-cancer screening incumbents (mammography, colonoscopy, low-dose CT) defending turf through clinical guideline influence and reimbursement advocacy
Cash runway risk - With $600M annual burn and $100M revenue, company requires continued equity financing or strategic partnership to fund operations through profitability, risking significant dilution at unfavorable valuations
Liquidity constraints if capital markets deteriorate - While current ratio is strong at 7.61x, absolute cash position must support multi-year commercialization timeline with no guarantee of positive inflection
moderate - As a pre-revenue healthcare diagnostics company, GRAIL has limited direct exposure to GDP cycles, but discretionary healthcare spending affects self-pay test adoption. In economic downturns, consumers may defer $949 out-of-pocket screening tests, though insured/Medicare-covered testing would be more resilient. The company's ability to raise capital for ongoing operations is highly sensitive to biotech funding cycles and risk appetite in equity markets.
Rising interest rates negatively impact GRAIL through multiple channels: (1) higher discount rates compress valuations of long-duration cash flows for pre-profitable companies, (2) reduced biotech sector risk appetite limits financing options and increases cost of capital, (3) opportunity cost makes speculative healthcare investments less attractive versus risk-free rates. With $600M annual cash burn and no near-term profitability, GRAIL requires continued access to capital markets where rate environment significantly affects funding availability and terms.
Minimal direct credit exposure as GRAIL operates with negligible debt (0.03 D/E ratio) and strong current ratio of 7.61x. However, the company faces indirect credit sensitivity through healthcare system customers' financial health and payers' willingness to cover novel diagnostics during periods of healthcare budget constraints. Tighter credit conditions could also limit partnership opportunities with cash-constrained hospital networks.
growth - GRAIL attracts speculative growth investors focused on transformative healthcare technology with massive addressable market ($50B+ global cancer screening opportunity) but accepting of binary regulatory/reimbursement risk and extended timeline to profitability. The stock appeals to biotech specialists, thematic healthcare investors betting on liquid biopsy adoption, and crossover funds willing to hold through 3-5 year commercialization cycle. Not suitable for value or income investors given negative earnings, no dividends, and valuation based entirely on discounted future cash flows contingent on successful regulatory and commercial execution.
high - Stock exhibits extreme volatility with 205% six-month return reflecting binary event-driven catalysts around regulatory decisions, clinical data releases, and reimbursement announcements. As pre-profitable company with limited analyst coverage and concentrated institutional ownership, GRAIL experiences significant price swings on low-volume days and outsized reactions to sector sentiment shifts. Implied volatility typically elevated around scheduled FDA action dates and earnings releases where guidance updates on regulatory timelines drive reassessment of probability-weighted outcomes.
